xiliertinib   Click here for help

GtoPdb Ligand ID: 9929

Synonyms: HMPL-309 | HMPL309 | theliatinib
Compound class: Synthetic organic
Comment: Xiliertinib (HMPL-309) is an ATP-competitive EGFR tyrosine kinase inhibitor that was developed for anticancer potential [1].
Theliatinib appears to be a 'pseudo' INN, that uses the -tinib INN stem for tyrosine kinase inhibitors, but was not submitted to the World Health Organisation for ratification.
Click here for help
2D Structure
Click here for help
Click here for structure editor
Physico-chemical Properties
Click here for help
Hydrogen bond acceptors 8
Hydrogen bond donors 2
Rotatable bonds 6
Topological polar surface area 81.56
Molecular weight 444.23
XLogP 1.4
No. Lipinski's rules broken 0
Click here for help
Canonical SMILES C#Cc1cccc(c1)NC1N=CN=C2C1C=C(NC(=O)N1CC3C(C1)CCN3C)C(=C2)OC
Isomeric SMILES C#Cc1cccc(c1)NC1N=CN=C2C1C=C(NC(=O)N1C[C@H]3[C@@H](C1)CCN3C)C(=C2)OC
InChI InChI=1S/C25H28N6O2/c1-4-16-6-5-7-18(10-16)28-24-19-11-21(23(33-3)12-20(19)26-15-27-24)29-25(32)31-13-17-8-9-30(2)22(17)14-31/h1,5-7,10-12,15,17,19,22,24,28H,8-9,13-14H2,2-3H3,(H,29,32)/t17-,19?,22+,24?/m1/s1
No information available.
Summary of Clinical Use Click here for help
A Phase 1 clinical study designed to evaluate theliatinib efficacy in patients with advanced EGFR-driven solid tumours in China (NCT02601274) is marked as terminated. The reason for termination is stated as a change in the developer's clinical development plan.
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT02601274 Study of Theliatinib (HMPL-309) in Patients With Advanced Solid Tumor Phase 1 Interventional Hutchison Medipharma Limited